Teva Takes FDA To Court In Challenge To “Authorized” Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic firm sues FDA, asserting the agency exceeded its expertise in finding that the marketing of “brand generics” during a first-filer’s 180-day exclusivity period promotes competition. Teva’s lawsuit in D.C. federal court comes two weeks after Mylan filed a separate, but similar, action against FDA in West Virginia.